What is Compass Therapeutics?
Headquartered in Boston, Massachusetts, Compass Therapeutics is a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of novel antibody-based therapeutics. The company's research focus is primarily centered on oncology, specifically addressing the mechanisms of angiogenesis and tumor vascularization. Its lead product candidates, including the bispecific antibody CTX-009 and the CD137 agonist CTX-471, represent a sophisticated approach to modulating immune responses and disrupting tumor growth pathways. By targeting critical signaling pathways such as Notch-1 and PD-1/PD-L1, the company is positioning itself as a key player in the next generation of precision immunotherapy, aiming to improve patient outcomes through highly specific, mechanism-driven drug design.
How much funding has Compass Therapeutics raised?
Compass Therapeutics has raised a total of $213.8M across 3 funding rounds:
Private Equity
$21.8M
Series A
$132M
Share Placement
$60M
Private Equity (2017): $21.8M, investors not publicly disclosed
Series A (2018): $132M led by Biomatics Capital, Alexandria Venture Investments, OrbiMed, Cowen Healthcare Investments, Ulysses Diversified Holdings, Borealis Ventures, Thiel Capital, F-Prime Capital Partners, and Biomed Realty Ventures
Share Placement (2020): $60M supported by Olivia Ventures
Key Investors in Compass Therapeutics
Biomatics Capital
Biomatics Capital is a for-profit venture firm focused on investing in transformative data-enabled innovations at the intersection of health care and technology.
Alexandria Venture Investments
Alexandria Real Estate Equities, Inc. is a real estate investment trust that provides specialized laboratory and office space for the life sciences and biotechnology industries.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics.
What's next for Compass Therapeutics?
With the recent influx of capital, Compass Therapeutics is well-positioned to accelerate its clinical trial programs and expand its research capabilities. The strategic focus will likely remain on the maturation of its bispecific and monoclonal antibody portfolio, with an emphasis on achieving key clinical milestones that validate the efficacy of its therapeutic candidates. As the company navigates the complexities of the oncology market, the focus will shift toward operational scaling and potential collaborative partnerships that can further enhance its drug development pipeline. The firm's ability to leverage its existing intellectual property and scientific expertise will be paramount in maintaining its competitive edge in the rapidly evolving landscape of oncology-focused biotechnology.
See full Compass Therapeutics company page
